Drug intelligence / Profile preview

ezetimibe + simvastatin

Development stage: Unknown
Lead developer: Pescado Pharm
Modality: Small Molecules
Administration: Oral

Overview

**Timbestatin** is an oral fixed-dose lipid-lowering combination of ezetimibe and simvastatin. Ezetimibe inhibits intestinal cholesterol uptake through Niemann-Pick C1-like protein 1, while simvastatin is an HMG-CoA reductase inhibitor that reduces hepatic cholesterol synthesis and increases clearance of circulating low-density lipoprotein cholesterol. Pescado lists Timbestatin as film-coated tablets in a 10 mg ezetimibe plus 20 mg simvastatin strength and also lists a 10 mg ezetimibe plus 40 mg simvastatin presentation in its pipeline for lipid lowering.

Brand names: Timbestatin
Other names: ezetimibe/simvastatin

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on ezetimibe + simvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ezetimibe + simvastatin.

Explore the full profile